Literature DB >> 15754414

Liver cirrhosis as a consequence of iron overload caused by hereditary nonspherocytic hemolytic anemia.

Philip Hilgard1, Guido Gerken.   

Abstract

Nonspherocytic hereditary anemias are occasionally accompanied by significant iron overload but the significance for the development of chronic liver disease is not clear. We described two cases of patients with chronic liver disease and severe iron overload due to chronic hereditary hemolysis. Both patients have had signs of liver cirrhosis and severe hemolysis since childhood. A hereditary pyruvate kinase deficiency (PKD) was discovered as the underlying reason for the hemolysis. Sequencing of the pyruvate kinase gene showed a mutation within exon 11. Liver histology in both patients revealed cirrhosis and a severe iron overload but primary hemochromatosis was excluded by HFE-gene analysis. An iron reduction therapy with desferrioxamine led to significant decrease of serum ferritin and sustained clinical improvement. PKD-induced hemolysis may cause severe iron overload even in the absence of HFE-genotype abnormalities. This secondary iron overload can lead to chronic liver disease and cirrhosis. Therefore, the iron metabolism of PKD patients has to be closely monitored and iron overload should be consequently treated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754414      PMCID: PMC4250723          DOI: 10.3748/wjg.v11.i8.1241

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Six previously undescribed pyruvate kinase mutations causing enzyme deficiency.

Authors:  A Demina; K I Varughese; J Barbot; L Forman; E Beutler
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

Review 2.  Tissue iron overload and mechanisms of iron-catalyzed oxidative injury.

Authors:  E J Lesnefsky
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

3.  Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients.

Authors:  P D Jensen; F T Jensen; T Christensen; J Ellegaard
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

4.  Molecular study of pyruvate kinase deficient patients with hereditary nonspherocytic hemolytic anemia.

Authors:  L Baronciani; E Beutler
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

5.  Factors affecting erythrocyte ferritin content in thalassaemia intermedia.

Authors:  A Piperno; M Sampietro; M T Taddei; G Fiorelli
Journal:  Br J Haematol       Date:  1984-01       Impact factor: 6.998

6.  Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia.

Authors:  C Lenzner; P Nürnberg; G Jacobasch; C Gerth; B J Thiele
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

7.  Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: study of Italian cases.

Authors:  A Zanella; P Bianchi; A Iurlo; C Boschetti; E Taioli; C Vercellati; M Zappa; E Fermo; D Tavazzi; M Sampietro
Journal:  Blood Cells Mol Dis       Date:  2001 May-Jun       Impact factor: 3.039

8.  Hereditary pyruvate kinase deficiency: role of the abnormal enzyme in red cell pathophysiology.

Authors:  A Zanella; P Rebulla; C Vullo; C Izzo; F Tedesco; G Sirchia
Journal:  Br J Haematol       Date:  1978-12       Impact factor: 6.998

9.  Retrovirus-mediated gene transfer of human pyruvate kinase (PK) cDNA into murine hematopoietic cells: implications for gene therapy of human PK deficiency.

Authors:  K Tani; T Yoshikubo; K Ikebuchi; K Takahashi; T Tsuchiya; S Takahashi; M Shimane; H Ogura; A Tojo; K Ozawa
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

Review 10.  Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes.

Authors:  S Miwa; H Fujii
Journal:  Am J Hematol       Date:  1996-02       Impact factor: 10.047

View more
  4 in total

1.  Prominent basophilic stippling and hemochromatosis in glucose-6-phosphate dehydrogenase deficiency.

Authors:  Sam Vander Meeren; An Van Damme; Kristin Jochmans
Journal:  Int J Hematol       Date:  2014-12-09       Impact factor: 2.490

2.  Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency.

Authors:  Maria Garcia-Gomez; Andrea Calabria; Maria Garcia-Bravo; Fabrizio Benedicenti; Penelope Kosinski; Sergio López-Manzaneda; Collin Hill; María Del Mar Mañu-Pereira; Miguel A Martín; Israel Orman; Joan-LLuis Vives-Corrons; Charles Kung; Axel Schambach; Shengfang Jin; Juan A Bueren; Eugenio Montini; Susana Navarro; Jose C Segovia
Journal:  Mol Ther       Date:  2016-05-03       Impact factor: 11.454

3.  Bilirubin cholelithiasis and haemosiderosis in an anaemic pyruvate kinase-deficient Somali cat.

Authors:  C van Geffen; K Savary-Bataille; K Chiers; U Giger; S Daminet
Journal:  J Small Anim Pract       Date:  2008-08-05       Impact factor: 1.522

4.  Appraisal of patient-reported outcome measures in analogous diseases and recommendations for use in phase II and III clinical trials of pyruvate kinase deficiency.

Authors:  M S Salek; T Ionova; J R Johns; E N Oliva
Journal:  Qual Life Res       Date:  2018-11-19       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.